NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
Clinical Trials
32 trialsNCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT05613088 2025-10-20
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT02514447 2025-09-25
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy
G1 Therapeutics, Inc.
Phase 1/2 Completed
NCT05092360 2025-08-28
ARTISTRY-7
Mural Oncology, Inc
Phase 3 Terminated
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT03088813 2025-02-19
RESILIENT
Ipsen
Phase 3 Completed
NCT04029688 2024-12-20
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT05246111 2024-11-22
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT04768296 2024-09-26
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
Phase 2 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02200757 2024-06-25
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 2 Completed
NCT01076400 2023-09-18
MK-1775-008
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT02481830 2023-07-27
CheckMate331
Bristol-Myers Squibb
Phase 3 Completed
NCT00976911 2022-06-21
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT03061812 2021-02-23
TAHOE
AbbVie
Phase 3 Completed
NCT03098030 2020-12-09
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
United Therapeutics
Phase 2/3 Completed
NCT02631876 2020-10-14
FORWARD I
ImmunoGen, Inc.
Phase 3 Completed
NCT02421588 2020-04-03
CORAIL
PharmaMar
Phase 3 Completed
NCT00065182 2019-06-24
Comparison of IV Topotecan/Docetaxel to Docetaxel Alone in Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed
NCT02100007 2017-10-02
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
Phase 1/2 Terminated
NCT01684878 2017-05-23
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
Hoffmann-La Roche
Phase 3 Completed
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00437073 2015-10-15
Brain Metastases In ErbB2-Positive Breast Cancer
GlaxoSmithKline
Phase 2 Terminated
NCT01121406 2015-08-13
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00316186 2015-05-07
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
GlaxoSmithKline
Phase 2 Completed
NCT01500720 2015-04-13
Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer
Sanofi
Phase 2 Completed
NCT00390806 2014-01-20
Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00316173 2012-11-27
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00267488 2012-07-11
Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00698516 2012-03-27
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
GlaxoSmithKline
Phase 2 Completed